AVROBIO (AVRO) Registration Filing summary

Company overview and business model

• Clinical-stage biotech focused on developing biologics targeting G protein-coupled receptors (GPCRs) for diseases with significant unmet medical need.

• Proprietary GEODe™ platform enables discovery and development of GPCR-targeted proteins and antibodies.

• Lead asset TX45 is an Fc-relaxin fusion for Group 2 pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); TX2100 targets hereditary hemorrhagic telangiectasia (HHT).

• Pipeline includes a bispecific GPCR modulator for fibrotic diseases.

Financial performance and metrics

• Reported net loss of $58.0 million for 2024 and $42.8 million for 2023; accumulated deficit of $148.6 million as of December 31, 2024.

• Research and development expenses increased 12% to $41.4 million in 2024; general and administrative expenses rose 117% to $16.7 million.

• Cash and cash equivalents of $141.2 million as of December 31, 2024; $185 million raised in February 2025 private placement.

• No revenue generated to date; expects continued operating losses as development progresses.

Use of proceeds and capital allocation

• Proceeds from the private placement are intended to fund ongoing R&D, clinical trials, and general corporate purposes.

• Company will not receive proceeds from the resale of shares by selling stockholders in this offering.

• Cash runway expected to last at least 12 months from financial statement issuance.